However, a 2015 paper investigating 672 Italian ALS patients identified a significantly shorter survival in case of ATXN2 positive patients compared to ATXN2 negative patients (2.0 years vs. 3.2 years). This evidence concerns the gene ATXN2 and amyotrophic lateral sclerosis.